U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
951 articles with Allergan, Inc.
Reportedly, Madrigal Pharmaceuticals is considering a sale. After receiving interest from other big drug companies, the nine-employee company is evaluating its options.
Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension
Allergan plc announced the release of new topline clinical trial data on Bimatoprost SR, the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bimatoprost SR is designed to lower IOP for at least 4 months, achieving clinical goals while freeing patients from daily eye drop regimens.
The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease is somewhat low.
Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial
Study meets primary endpoint for all doses and dose regimens
Know Your Birth Control® Launches New 'BC Trivia' Quiz to Encourage Informed Conversations Around Contraception.
After two of Allergan’s investors, Appaloosa Management and Senator Investment Group, wrote to the company’s board asking that Brent Saunders’ duties be split up, legendary investor Carl Icahn appears to be building a position in the company—again.
Unity Biotechnology has raised $222 million in venture capital, raised $85 million in an initial public offering (IPO) in May, and has a value of $700 million. All without having a product to sell.
Appaloosa Management’s David Tepper and Senator Investment Group’s Douglas Silverman sent a letter to Allergan’s board of directors yesterday asking—or demanding—that the company split the roles of chief executive officer and chairman.
Allergan plc issued the following statement in response to a public shareholder letter.
Appaloosa LP and Senator Investment Group LP sent a letter to Allergan plc’s Board of Directors.
Allergan Teams Up with a Host of Celebrities to Encourage Alzheimer's Patients and their Caregivers to Hold on to Hope
The 'Hold on to Hope' movement takes to social media in recognition of Alzheimer's & Brain Awareness during the month of June
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
Allergan will sell off two non-core businesses following a strategic review of the company’s assets, according to multiple reports.
The standard physician sample pack of Allergan’s Taytulla birth control pills should have 24 pink capsules that contain hormones with four maroon capsules at the end of the package cycle that do not have hormones. However, 170,000 packages had four maroon placebos located at the beginning of the ...
5/29/2018It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules
Allergan, plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy.
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
A day after Illinois-based Aptinyx strengthened its relationship with pharma giant Allergan, the company is now eying an $80 million initial public offering of stock on the Nasdaq Exchange.
Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator
Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.